Human CXCL14/BRAK Antibody
Human CXCL14/BRAK Antibody Summary
Accession # O95715
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
CXCL14/BRAK (breast and kidney-expressed chemokine), also named MIP-2 gamma, KEC (kidney-expressed chemokine), and BMAC (B cell and monocyte-activating chemokine), is a member of CXC chemokine superfamily (1 - 5). The deduced 99 amino acid (aa) residue precursor has a 22 aa putative signal peptide that is cleaved to produce the 77 aa mature protein. Mature human and mouse CXCL14 differ by only 2 residues. Human CXCL14 shares approximately 30% aa sequence identity with MIP-2 alpha (GRO beta ) as well as MIP-2 beta (GRO gamma ). The gene for CXCL14 has been mapped human chromosome 5q31. Unlike the MIP-2 chemokines, CXCL14 lacks the ELR domain preceding the CXC motif. CXCL14 transcripts are constitutively expressed at high levels in the basal layer of epidermal keratinocytes and dermal fibroblasts of skin tissues as well as lamina propria cells in normal intestinal tissues. CXCL14 has been shown to be a highly selective chemoattractant for monocytes that have been treated with prostaglandin E2 or forskolin, agents that activate adenylate cyclase. CXCL14 has been proposed to be important for regulating the trafficking of macrophage precursor to regions in skin and mucosal tissues that support their development. Consistent with this hypothesis, macrophages were frequently found to co-localize with CXCL14-producing cells in the dermis and lamina propria.
- Hromas, R. et al. (1999) Biochem. Biophys. Res. Commun. 255:703.
- Cao, X. et al. (2000) J. Immunol. 165:2588.
- Kurth, I. et al. (2001) J. Exp. Med. 194:855.
- Frederick, M.J. et al. (2000) Am. J. Pathol. 156:1937.
- Sleeman, M.A. et al. (2000) Int. Immunol. 12:677.
Citations for Human CXCL14/BRAK Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 2
Filter your results:
Fascaplysin Exerts Anti-Cancer Effects through the Downregulation of Survivin and HIF-1? and Inhibition of VEGFR2 and TRKA
Authors: TI Oh, YM Lee, TJ Nam, YS Ko, S Mah, J Kim, Y Kim, RH Reddy, YJ Kim, S Hong, JH Lim
Int J Mol Sci, 2017;18(10):.
Sample Types: Tissue Homogenates
Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively.
Authors: Tracey L, Perez-Rosado A, Artiga MJ, Camacho FI, Rodriguez A, Martinez N, Ruiz-Ballesteros E, Mollejo M, Martinez B, Cuadros M, Garcia JF, Lawler M, Piris MA
J. Pathol., 2005;206(2):123-34.
Sample Types: Whole Cells
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human CXCL14/BRAK Antibody
There are currently no reviews for this product. Be the first to review Human CXCL14/BRAK Antibody and earn rewards!
Have you used Human CXCL14/BRAK Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image